Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unipeg and Ribazole in Chronic Hepatitis C (EUROP)
NCT02601976Phase 4Completed
- Sponsor
- Getz Pharma
- Start
- Aug 2010
- Primary completion
- Sep 2012
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a in hepatitis C (HCV), sponsored by Getz Pharma. Primary endpoints: Sustained Virological Response and End Treatment Response up to 48 weeks. Started Aug 2010; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02601976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601976.